Pfizer (NYSE:PFE) Trading 2% Higher – Here’s Why

Pfizer Inc. (NYSE:PFE) shares traded up 2% during mid-day trading on Monday . The company traded as high as $28.70 and last traded at $28.51. 44,692,075 shares traded hands during mid-day trading, an increase of 7% from the average session volume of 41,789,922 shares. The stock had previously closed at $27.96.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Oncology pipeline supports long-term growth: Pfizer’s oncology strategy is centered on Padcev, supported by potential label expansions and pipeline candidates such as PF-08634404. Investors may view this portfolio as important for offsetting revenue pressure from older products and strengthening growth beyond COVID-related products. From Padcev to PF-08634404: Pfizer’s Oncology Growth Push
• Positive Sentiment: Dividend appeal is supporting demand: Pfizer is being highlighted as a high-yielding defensive stock as investors seek income and become more cautious about elevated technology and artificial-intelligence valuations. Its dividend may help support the shares while the company executes its growth plan. 3 Stocks for Investors Who Still Believe Cash Is King
• Positive Sentiment: Higher earnings expectations: Erste Group Bank increased its fiscal 2026 EPS estimate for Pfizer, adding to the constructive analyst outlook. Pfizer’s latest quarterly results also exceeded consensus estimates for earnings and revenue, while management’s full-year EPS guidance remains $2.80–$3.00. Pfizer FY2026 EPS Estimate Increased by Erste Group Bank
• Neutral Sentiment: Recovery remains a work in progress: Pfizer has raised its outlook, but analysts characterize its turnaround as less visible than some other companies’ recoveries. This reinforces the potential for gradual improvement rather than an immediate acceleration in results. Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn’t
• Negative Sentiment: Relative performance remains a concern: Pfizer has underperformed the S&P 500 over the past year, highlighting ongoing investor concerns about growth, execution, and the company’s post-pandemic revenue transition. Analysts remain moderately optimistic, but the underperformance could limit enthusiasm for the stock. Is Pfizer Stock Underperforming the S&P 500?

Analyst Upgrades and Downgrades

Several research firms have weighed in on PFE. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. UBS Group restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Finally, JPMorgan Chase & Co. lowered their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company’s fifty day moving average price is $25.55 and its 200 day moving average price is $26.30. The company has a market cap of $162.50 billion, a PE ratio of 37.51 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.0%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is presently 226.32%.

Institutional Trading of Pfizer

A number of large investors have recently added to or reduced their stakes in PFE. Evolution Wealth Management Inc. grew its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the period. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Keb Asset Management LLC purchased a new position in Pfizer in the second quarter valued at approximately $26,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Finally, Field & Main Bank bought a new position in Pfizer during the second quarter valued at $27,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.